SCHEMBL6717581

SCHEMBL6717581

O=C(Nc1ccc(Cl)cc1)C(c1ccccc1)N(S)C(=O)Nc1ccccc1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 1/20 0.47
CNR1 P21554 1/20 0.46
ALDH1A1 P00352 5/20 0.44
GAA P10253 3/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
KDM4E B2RXH2 1/20 0.44
NPC1 O15118 1/20 0.44
THRB P10828 1/20 0.44
RAB9A P51151 1/20 0.44
NOX1 Q9Y5S8 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
CASR P41180 2/20 0.42
POLB P06746 2/20 0.40
LMNA P02545 1/20 0.40
PCTP Q9UKL6 1/20 0.40
MAPK1 P28482 1/20 0.40
ATM Q13315 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
IGF1R P08069 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6724008 0.89 KMT2A (0.54) GRIK1ALDH1A1GAAKMT2AMEN1
SCHEMBL6714154 0.88 CASR (0.47) GRIK1ALDH1A1GAAKMT2AMEN1
SCHEMBL6717048 0.86 GRIK1 (0.48) GRIK1ALDH1A1GAAKMT2AKDM4E
SCHEMBL6715503 0.84 POLB (0.44) CNR1ALDH1A1KMT2AMEN1KDM4E
SCHEMBL6714006 0.82 ALDH1A1 (0.45) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL6715754 0.82 MAPT (0.46) CNR1ALDH1A1KMT2AMEN1KDM4E
SCHEMBL6717563 0.82 POLB (0.43) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL6716817 0.81 POLB (0.42) CNR1ALDH1A1KMT2AMEN1KDM4E
SCHEMBL6717397 0.81 LMNA (0.53) ALDH1A1GAAKMT2AMEN1KDM4E
SCHEMBL6717353 0.80 PHGDH (0.50) ALDH1A1GAAKMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 GRIK1 121/4885CNR1 472/4885ALDH1A1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.